Notice Number: NOT-CA-18-114
Key Dates
Release Date: September 26, 2018
PAR-18-880
NOT-CA-18-107 - RESCINDED
Issued by
National Cancer Institute (NCI)
Purpose
The purpose of this Notice is to correct the Additional Information on Eligibility and Number of Applications in Funding Opportunity Announcement (FOA) PAR-18-880, NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed).
The following section of the FOA has been corrected:
Section III. Eligibility Information, Additional Information on Eligibility
Number of Applications
Currently reads:
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).
Should correctly read (in italics):
To prevent a lapse in funding, a PD/PI may submit a competitive R01 application and an OIA application in parallel. Should both applications be meritorious and considered for funding, the PD/PI may be permitted to accept only one of the awards pending negotiation with IC staff.
All other aspects of this FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Christine Siemon
National Cancer Institute (NCI)
Telephone: 240-276-6180
Email: [email protected]
and Human Services (HHS)
